Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy

Avik Chakraborty,Arpit Mitra,Megha Tawate,Sudip Sahoo,Sangita Lad,Sutapa Rakshit,Sujay Gaikwad,Sandip Basu,Hemant Shimpi,Sharmila Banerjee

Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy

2021

Avik Chakraborty
Arpit Mitra
Megha Tawate
Sudip Sahoo
Sangita Lad
Sutapa Rakshit
Sujay Gaikwad
Sandip Basu
Hemant Shimpi
Sharmila Banerjee

Introduction: [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 has emerged as a promising radiopharmaceutical for targeting PSMA in metastatic castrate-resistant prostate carcinoma (mCRPC). ...

Keywords:

clinical efficacy
177Lu-PSMA-617
Internal medicine
prostate carcinoma
Oncology
ready to use
clinical study
membrane antigen
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations